Scholarlink

Purpose of Review <p>This narrative review explores the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists in the management of hidradenitis suppurativa (HS). Given the strong association between HS, obesity, and metabolic syndrome, these agents may offer therapeutic benefit through their anti-inflammatory and metabolic effects.</p> Recent Findings <p>Recent small observational studies and case reports have documented improvements in quality of life, flare frequency, and disease severity among HS patients treated with GLP-1RAs such as liraglutide, semaglutide, dulaglutide, exenatide, and tirzepatide. Proposed mechanisms include weight loss, systemic anti-inflammatory effects, and improved bioavailability of HS medications. However, the evidence remains primarily anecdotal and heterogeneous.</p> Summary <p>GLP-1RAs may serve as a promising adjunctive therapy for HS, particularly in patients with metabolic comorbidities. Although early observational studies report improvements in HS severity, larger, randomized controlled trials are needed to establish their role in HS disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Hidradenitis Suppurativa: A Narrative Review

  • 期刊论文

  • 发表日期：

    2025年10月4日

查看全文
  • Abizairie Sánchez-Feliciano,
  • Jenna K. Currier,
  • John S. Barbieri,
  • Alexandra Charrow

摘要

Purpose of Review

This narrative review explores the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists in the management of hidradenitis suppurativa (HS). Given the strong association between HS, obesity, and metabolic syndrome, these agents may offer therapeutic benefit through their anti-inflammatory and metabolic effects.

Recent Findings

Recent small observational studies and case reports have documented improvements in quality of life, flare frequency, and disease severity among HS patients treated with GLP-1RAs such as liraglutide, semaglutide, dulaglutide, exenatide, and tirzepatide. Proposed mechanisms include weight loss, systemic anti-inflammatory effects, and improved bioavailability of HS medications. However, the evidence remains primarily anecdotal and heterogeneous.

Summary

GLP-1RAs may serve as a promising adjunctive therapy for HS, particularly in patients with metabolic comorbidities. Although early observational studies report improvements in HS severity, larger, randomized controlled trials are needed to establish their role in HS disease management.